PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection is a research paper published in PLoS Pathogens (2021). On theSindex it has a DataRank of 1.5. It has been cited 60 times, with 41 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.617
From this paper's citation signal
Citation Network Contribution
0.915
From 31 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 41 citers.
National Institute of Allergy and Infectious Diseases
Grant: HHSN272201300019I
National Institute of Allergy and Infectious Diseases
Grant: 2R44AI058375-11
NIAID NIH HHS
Grant: HHSN272201300019C
NIAID NIH HHS
Grant: R44 AI058375
National Institutes of Health
Grant: 2R44AI058375-09
Universal Attenuated Sporozoite Vaccine and Challenge System
FWCI
8.35
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Whole sporozoite immunization with Plasmodium falciparum strain NF135 in a randomized trial
Additional file 1 of Whole sporozoite immunization with Plasmodium falciparum strain NF135 in a randomized trial